Observation on the clinical efficacy of diquafosol sodium combined with fluorometholone in treatment of dry eye syndrome

LI Yue; JIANG Li; LI Jinfen; HUANG Hui; LAN Qianqian; QIN Yuanjun; XIONG Jiawei; LIAO Tao; XU Fan

doi:10.3969/j.issn.1674-3806.2025.02.13

Abstract：Objective To observe the clinical efficacy of diquafosol sodium(DQS)combined with fluorometholone in treatment of dry eye syndrome.Methods A total of 76 dry eye syndrome patients admitted to Department of Ophthalmology,the People's Hospital of Guangxi Zhuang Autonomous Region in 2023 were recruited and were randomly divided into control group and observation group according to the patient's visit sequence,with 38 cases in each group.The observation group was treated with DQS combined with fluorometholone,and the control group was treated with sodium hyaluronate combined with fluorometholone.The patients'right eyes were selected to be observed and analyzed.The ocular surface disease index(OSDI)scores,relevant indicators of tear secretion[results of Schirmer Ⅰ test(SⅠt),tear meniscus height(TMH)],tear film stability indicators[fluorescein breakup time(FBUT),first noninvasive breakup time(F-NIBUT),and average noninvasive breakup time(A-NIBUT)],corneal fluorescein staining(CFS)scores,meibomian gland examination indicators(meibomian gland opening status scores,meibomian gland grading scores,meibomian gland secretion trait scores),intraocular pressure,and the occurrence of adverse drug reactions were compared between the two groups before and after treatment.Results The OSDI scores in both groups after treatment were significantly decreased compared with those before treatment(P＜0.05),and the posttherapeutic OSDI scores in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the results of SⅠt in the observation group were significantly higher than those in the control group(P＜0.05),and there was no significant difference in TMH between the two groups(P＞0.05).After treatment,FBUT,F-NIBUT and A-NIBUT in both groups were significantly prolonged compared those before treatment(P＜0.05),and the levels of the indicators in the observation group were longer than those in the control group,and the differences were statistically significant(P＜0.05).The CFS scores in both groups after treatment were significantly decreased compared with those before treatment(P＜0.05),but there were no significant differences in the CFS scores between the two groups(P＞0.05).Compared with those before treatment,the meibomian gland opening status scores and meibomian gland secretion trait scores were significantly decreased in both groups after treatment(P＜0.05),but the changes in the meibomian gland grading scores were not significant(P＞0.05).Before and after treatment,there were no significant differences in the meibomian gland grading scores,meibomian gland opening status scores and meibomian gland secretion trait scores between the two groups(P＞0.05).During the treatment period,no adverse events were observed in both groups.There were no significant changes in intraocular pressure between the two groups before and after treatment(P＞0.05).Conclusion Diquafosol sodium combined with fluorometholone can effectively improve the clinical symptoms and signs of the dry eye syndrome patients,and the effects of diquafosol sodium combined with fluorometholone are better than those of sodium hyaluronate combined with fluorometholone,and diquafosol sodium combined with fluorometholone is worthy of clinical application and promotion.